Skip to content

Guavy Wire

Market news, scored and summarized
Lead story Stocks Johnson & Johnson Highlights Sjögren’s Disease Trial Results and Dividend Sustainability Johnson & Johnson disclosed findings from a midstage clinical trial of nipocalimab, emphasizing mouth dryness as the primary symptom Sjögren’s disease patients seek to alleviate. The stock offers a 1.92% dividend yield with a sustainable payout ratio of 57%, but it is currently 41.8% overvalued. The DAHLIAS trial showed promising results, with 33% of patients on a higher dose experiencing increased saliva production. Insider activity indicates net selling, while guru investors show mixed adjustments. Investors should weigh the dividend appeal against the stock’s premium valuation. Sentiment -2 Clout 70 Speculation 3 JNJ

Earlier in Commodities

All Commodities leads

Earlier in Crypto

All Crypto leads

Earlier in Forex

All Forex leads

Earlier in Stocks

All Stocks leads